At a glance
- Originator Boehringer Ingelheim
- Developer Research Biochemicals
- Class Anti-ischaemics; Antiarrhythmics; Antihypertensives
- Mechanism of Action Alpha 1 adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Arrhythmias; Hypertension; Premature ejaculation; Reperfusion injury
Most Recent Events
- 16 Oct 2003 Discontinued - Preclinical for Arrhythmias in USA (unspecified route)
- 16 Oct 2003 Discontinued - Preclinical for Premature ejaculation in Taiwan (unspecified route)
- 16 Oct 2003 Discontinued - Preclinical for Reperfusion injury in Japan (unspecified route)